One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial

Aliment Pharmacol Ther. 2002 Jul;16(7):1261-7. doi: 10.1046/j.1365-2036.2002.01278.x.

Abstract

Background: Seven-day triple therapy including omeprazole, clarithromycin and amoxicillin has become the treatment of choice for Helicobacter pylori infection. However, 7 days of classical quadruple therapy combining omeprazole, tetracycline, metronidazole and bismuth may be an alternative to triple therapy.

Aim: To compare triple vs. quadruple therapy for H.pylori eradication.

Methods: Three hundred and thirty-nine patients with peptic ulcer and H. pylori infection were included in the study. Patients were randomized to receive omeprazole, 20 mg, amoxicillin, 1 g, and clarithromycin, 500 mg, all b.d., or omeprazole, 20 mg b.d., tetracycline chloride, 500 mg, metronidazole, 500 mg, and bismuth subcitrate, 120 mg, all t.d.s. Cure was defined as a negative urea breath test at least 2 months after treatment.

Results: Per protocol and intention-to-treat cure rates were 86%[95% confidence interval (CI), 80-91%] and 77% (95% CI, 70-83%) for triple therapy, and 89% (95% CI, 82-93%) and 83% (95% CI, 76-88%) for quadruple therapy. No significant differences between the groups were found in the cure rates, compliance or side-effects.

Conclusion: One-week triple and quadruple therapy show similar results when used as first-line eradication treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Breath Tests
  • Clarithromycin / therapeutic use
  • Drug Administration Schedule
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Male
  • Metronidazole / therapeutic use
  • Middle Aged
  • Omeprazole / therapeutic use
  • Organometallic Compounds / therapeutic use
  • Peptic Ulcer / drug therapy
  • Peptic Ulcer / microbiology*
  • Tetracycline / therapeutic use
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Organometallic Compounds
  • Metronidazole
  • Amoxicillin
  • Tetracycline
  • Clarithromycin
  • bismuth tripotassium dicitrate
  • Omeprazole